Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Maviret
Maviret 100 mg/40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-139027 · Präparat HOS-098268
Co-administration of Maviret with medicinal products that are moderate inducers P-gp/CYP3A may
decrease glecaprevir and pibrentasvir plasma concentrations (e.g. oxcarbazepine, eslicarbazepine,
lumacaftor, crizotinib). Co-administration of moderate inducers is not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): eslicarbazepine (HOS-120817) lumacaftor (HOS-139029) crizotinib (HOS-116818) oxcarbazepine (HOS-110224)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-15T12:56:00Z · SHA-256 225c0ba8f2354e64e1131849dc7b6e23a86b099b858b5f9e8bda200a3bdf07cd · Passage e9ef2c0e96059caecf4c29354efb93cc6c469df86853350888b55e90c7d3fdb3 · Zeichen 1947–2241 im Abschnitt
Wechselwirkungen · Maviret
Maviret 50 mg/20 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 32
HOS-139081 · Präparat HOS-098268
Co-administration of Maviret with medicinal products that are moderate inducers P-gp/CYP3A may
decrease glecaprevir and pibrentasvir plasma concentrations (e.g. oxcarbazepine, eslicarbazepine,
lumacaftor, crizotinib). Co-administration of moderate inducers is not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): eslicarbazepine (HOS-120817) lumacaftor (HOS-139029) crizotinib (HOS-116818) oxcarbazepine (HOS-110224)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-15T12:56:00Z · SHA-256 225c0ba8f2354e64e1131849dc7b6e23a86b099b858b5f9e8bda200a3bdf07cd · Passage e9ef2c0e96059caecf4c29354efb93cc6c469df86853350888b55e90c7d3fdb3 · Zeichen 2006–2300 im Abschnitt
Gegenanzeigen · Delstrigo
Delstrigo 100 mg/300 mg/245 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3
HOS-141142 · Präparat HOS-098610
Co-administration with medicinal products that are strong cytochrome P450 CYP3A enzyme inducers
is contraindicated as significant decreases in doravirine plasma concentrations are expected to occur,
which may decrease the effectiveness of Delstrigo (see sections 4.4 and 4.5). These medicinal
products include, but are not limited to the following:
• carbamazepine, oxcarbazepine, phenobarbital, phenytoin
• rifampicin, rifapentine
• St. John’s wort (Hypericum perforatum)
• mitotane
• enzalutamide
• lumacaftor
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumacaftor (HOS-139029) phenobarbital (HOS-085617) carbamazepine (HOS-085618) mitotane (HOS-112479) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) enzalutamide (HOS-116829)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T17:24:00Z · SHA-256 2c0deb57aeb6310e5014ea9012afd45619de92a00e9950f55a0cfcc2fdcdf2a8 · Passage fe61ee953492515bc94a98680d46a2de4cd17d7726126b16b4443bead6cd1ea8 · Zeichen 94–635 im Abschnitt
Wechselwirkungen · Delstrigo
Delstrigo 100 mg/300 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-141190 · Präparat HOS-098610
10
Recommendation concerning
Medicinal product by Effects on medicinal product levels co-administration with
therapeutic area geometric mean ratio (90 % CI)* doravirine/lamivudine/tenofovir
disoproxil
Calcium channel blockers
Interaction not studied with
doravirine or
doravirine/lamivudine/tenofovir
diltiazem disoproxil.
No dose adjustment is required.
verapamil
Expected:
doravirine
(Inhibition of CYP3A)
Cystic fibrosis treatment
Interaction not studied with
doravirine or
doravirine/lamivudine/tenofovir
lumacaftor disoproxil. Co-administration is
contraindicated.
Expected:
doravirine
(Induction of CYP3A)
Endothelin receptor antagonists
Interaction not studied with Co-administration should be
doravirine or avoided. If co-administration
doravirine/lamivudine/tenofovir cannot be avoided, a 100 mg dose
disoproxil. of doravirine should be taken
bosentan daily, approximately12 h after the
Expected: dose of
↓ doravirine doravirine/lamivudine/tenofovir
(Induction of CYP3A) disoproxil.
Hepatitis C antiviral agents
doravirine
AUC 1.56 (1.45, 1.68)
Cmax 1.41 (1.25, 1.58)
C24 1.61 (1.45, 1.79)
(Inhibition of CYP3A)
elbasvir + grazoprevir
elbasvir
(50 mg elbasvir QD +
AUC 0.96 (0.90, 1.02) No dose adjustment is required.
200 mg grazoprevir QD,
Cmax 0.96 (0.91, 1.01)
doravirine 100 mg QD)
C24 0.96 (0.89, 1.04)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) diltiazem (HOS-086288) elbasvir (HOS-108814) lumacaftor (HOS-139029) calcium (HOS-085615) grazoprevir (HOS-108815) bosentan (HOS-086291) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T17:24:00Z · SHA-256 2c0deb57aeb6310e5014ea9012afd45619de92a00e9950f55a0cfcc2fdcdf2a8 · Passage 629c30d2a096e5c26aa6137f5f1920bac824c07f9caca1e4ca776d46eb4450c2 · Zeichen 16171–18882 im Abschnitt
Gegenanzeigen · Pifeltro
Pifeltro 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3
HOS-141246 · Präparat HOS-098618
Co-administration with medicinal products that are strong cytochrome P450 CYP3A enzyme inducers
is contraindicated as significant decreases in doravirine plasma concentrations are expected to occur,
which may decrease the effectiveness of Pifeltro (see sections 4.4 and 4.5). These medicinal products
include, but are not limited, to the following:
• carbamazepine, oxcarbazepine, phenobarbital, phenytoin
• rifampicin, rifapentine
• St. John’s wort (Hypericum perforatum)
• mitotane
• enzalutamide
• lumacaftor
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumacaftor (HOS-139029) phenobarbital (HOS-085617) carbamazepine (HOS-085618) mitotane (HOS-112479) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) enzalutamide (HOS-116829)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T08:41:00Z · SHA-256 e669d0797aaecb09c38b8d2518d46b353834062d76517638eed9a33ed2fd94be · Passage e5fda511a0b33458147c32c880ed181b94fa7af09e5760fffbe53c8a96721df5 · Zeichen 93–634 im Abschnitt
Wechselwirkungen · Pifeltro
Pifeltro 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-141260 · Präparat HOS-098618
6
Medicinal product by Effects on medicinal product Recommendation concerning
therapeutic area levels geometric mean ratio co-administration with
(90 % CI)* doravirine
Antineoplastics
Interaction not studied.
Co-administration is
mitotane Expected:
contraindicated.
doravirine
(Induction of CYP3A)
Antipsychotics
Interaction not studied. Co-administration should be
avoided. If co-administration
Expected: cannot be avoided, one tablet of
thioridazine
↓ doravirine doravirine should be taken twice
(Induction of CYP3A) daily (approximately 12 hours
apart).
Azole antifungal agents
doravirine
ketoconazole AUC 3.06 (2.85, 3.29)
(400 mg QD, Cmax 1.25 (1.05, 1.49) No dose adjustment is required.
doravirine 100 mg SD) C24 2.75 (2.54, 2.98)
(Inhibition of CYP3A)
Interaction not studied.
fluconazole
itraconazole
Expected: No dose adjustment is required.
posaconazole
doravirine
voriconazole
(Inhibition of CYP3A4)
Calcium channel blockers
Interaction not studied.
diltiazem
Expected: No dose adjustment is required.
verapamil
doravirine
(CYP3A inhibition)
Cystic fibrosis treatment
Interaction not studied.
Co-administration is
lumacaftor Expected:
contraindicated.
doravirine
(Induction of CYP3A)
Endothelin receptor antagonists
Interaction not studied. Co-administration should be
avoided. If co-administration
Expected: cannot be avoided, one tablet of
bosentan
↓ doravirine doravirine should be taken twice
(Induction of CYP3A) daily (approximately 12 hours
apart).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) lumacaftor (HOS-139029) ketoconazole (HOS-084513) thioridazine (HOS-086281) calcium (HOS-085615) voriconazole (HOS-084524) itraconazole (HOS-084516) mitotane (HOS-112479) fluconazole (HOS-087945) bosentan (HOS-086291) posaconazole (HOS-085622) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T08:41:00Z · SHA-256 e669d0797aaecb09c38b8d2518d46b353834062d76517638eed9a33ed2fd94be · Passage 5857af90a9d74f14e161db872910bdea4a786d3d0f0bf2a7a9dd557c77554980 · Zeichen 9170–12349 im Abschnitt
Wechselwirkungen · Balversa
Balversa 3 mg film-coated tablets Balversa 4 mg film-coated tablets Balversa 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-151047 · Präparat HOS-100442
Strong or moderate CYP3A4 inducers
Co-administration with carbamazepine, a strong CYP3A4 and weak CYP2C9 inducer leads to
decreased erdafitinib exposure. Mean ratios of Cmax and AUC∞ for erdafitinib was 65.4% (90% CI:
60.8, 70.5) and 37.7% (90% CI: 35.4, 40.2), respectively, when co-administered with carbamazepine
relative to erdafitinib alone. Avoid co-administration of Balversa with strong CYP3A4 inducers (such
as apalutamide, enzalutamide, lumacaftor, ivosidenib, mitotane, rifapentine, rifampicin,
carbamazepine, phenytoin, and St. John’s wort). If Balversa is co-administered with a moderate
CYP3A4 inducer (such as dabrafenib, bosentan, cenobamate, elagolix, efavirenz, etravirine, lorlatinib,
mitapivat, modafinil, pexidartinib, phenobarbital, primidone, repotrectinib, rifabutin, sotorasib,
telotristat ethyl), the dose should be cautiously increased by 1 to 2 mg and adjusted gradually every
two to three weeks based on clinical monitoring for adverse reactions, not to exceed 9 mg. If the
moderate CYP3A4 inducer is discontinued, the Balversa dose may be adjusted as tolerated (see
sections 4.2 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumacaftor (HOS-139029) phenobarbital (HOS-085617) modafinil (HOS-090546) carbamazepine (HOS-085618) rifabutin (HOS-086262) apalutamide (HOS-086212) sotorasib (HOS-147831) etravirine (HOS-088088) dabrafenib (HOS-109452) telotristat ethyl (HOS-141158) mitapivat (HOS-147878) mitotane (HOS-112479) elagolix (HOS-112109) lorlatinib (HOS-140195) rifapentine (HOS-116386) ivosidenib (HOS-112046) efavirenz (HOS-087947) bosentan (HOS-086291) phenytoin (HOS-084531) repotrectinib (HOS-151068) enzalutamide (HOS-116829) pexidartinib (HOS-150766) cenobamate (HOS-146930) primidone (HOS-090551)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-23T15:29:41Z · SHA-256 9ba94a293568a63e1d68e3b08064d69d982961a4e8105cf8a7ed2e20ea28400b · Passage 37f802579316593a43bdb4de7805a7ac6e6865a9f601ae60d32e15b61a221f1c · Zeichen 1417–2535 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.